Table 1.
Channel | Agonist | Potency (EC50) | Antagonist | Potency (IC50) | References |
---|---|---|---|---|---|
TRPV1 | Capsaicin | 0.04–1 μM | Agatoxin 489 | 0.3 μM | Jung et al., 2001; Behrendt et al., 2004; Varga et al., 2005; Rami et al., 2006; Harteneck et al., 2011; Planells-Cases et al., 2011; Vetter and Lewis, 2011; Xia et al., 2011 |
Eugenol | 1 mM | Agatoxin 505 | 0.3 μM | ||
Resiniferatoxin | 39 nM | APHC1 | 54 nM | ||
Polygodial | 5 μM | Capsazepine | 420 nM | ||
Cinnamodial | 0.6 μM | Nicotine | 1 mM | ||
Isovelleral | 100 nM | Yohimbine | 25 μM | ||
Cannabidiol | 3 μM | Acetylsalicylic acid | 1 μM | ||
Ginsenoside Rc | ? | Grifolin | 26 μM | ||
VaTx1 | 12 μM | Neogrifolin | 7 μM | ||
VaTx2 | 3 μM | Albaconol | 17 μM | ||
VaTx3 | 0.3 μM | BCTC | 35 nM | ||
Leukotriene B4 | 30 μM | AMG-517 | 32 nM | ||
12-S-HPETE | 10 μM | SB366791 | 651 nM | ||
Anandamide | 30 μM | ||||
TRPA1 | Allyl isothiocyanate | 1–6.5 μM | Camphor | 0.6 mM | Karashima et al., 2007; Trevisani et al., 2007; Cruz-Orengo et al., 2008; Eid et al., 2008; Sculptoreanu et al., 2010; Harteneck et al., 2011; Vetter and Lewis, 2011; Trevisan et al., 2014; Wei et al., 2009; McGaraughty et al., 2010; Brenneis et al., 2011; Sisignano et al., 2012 |
Cinnamaldehide | 60μM | HC-030031 | 6.2 μM | ||
Methyl salicylate | 600 μM | A-967079 | 67 nM | ||
Allicin | 7.5 μM | Chembridge-5861528 | ? | ||
Ajoene | 0.5 μM | ||||
Diallyl trisufphide | 0.5 μM | ||||
Hydroxy-α-sanshool | 69 μM | ||||
Acrolein | 5 μM | ||||
Crotonaldehyde | 16 μM | ||||
Δ9 tetra-hydrocannabinol | 12 μM | ||||
Cannabinol | 20 μM | ||||
Hydrogen peroxide | ? | ||||
Nitrooleic acid | ? | ||||
4-hydroxy-2-nonenal | 27 μM | ||||
15-deoxy- Δ12,14-PGJ2 | ? | ||||
5,6-EET | ? | ||||
8,9-EET | ? | ||||
? |